Omalizumab beyond asthma

Allergologia et Immunopathologia

Volumn 40, Issue 5, 2012, Pages 306-315

  Sanchez, J ^a,b,c   Ramirez, R ^a   Diez, S ^a   Sus, S ^a   Echenique, A ^a   Olivares, M ^a,d   Cardona, R ^a,d  

^a Group of Clinical and Experimental Allergology (GACE)   (Colombia)

^b Foundation for Development of Medical and Biological Sciences (FUNDEMEB)   (Colombia)

^c UNIVERSIDAD DE CARTAGENA   (Colombia)

^d UNIVERSIDAD DE ANTIOQUIA   (Colombia)

Author keywords

Allergy; Anaphylaxis; Atopic dermatitis; Churg Strauss; Eczema; Eosinophilia; Mastocytosis; Omalizumab; Urticaria

Indexed keywords

HYMENOPTERA VENOM; IMMUNOGLOBULIN E; OMALIZUMAB; PLACEBO; SUPLATAST TOSYLATE;

ALLERGIC RHINITIS; ALLERGY; ANAPHYLAXIS; ASTHMA; ATOPIC DERMATITIS; CHURG STRAUSS SYNDROME; DRUG EFFICACY; DRUG SAFETY; EMBASE; EOSINOPHILIC COLITIS; EOSINOPHILIC ENTERITIS; EOSINOPHILIC ESOPHAGITIS; EOSINOPHILIC GASTROENTERITIS; EOSINOPHILIC GASTROINTESTINAL DISORDER; FOOD ALLERGY; HAY FEVER; HEVEA BRASILIENSIS; HUMAN; HYMENOPTERA VENOM ALLERGY; HYPER IGE SYNDROME; IDIOPATHIC DISEASE; LOW DRUG DOSE; MASTOCYTOSIS; MEDLINE; PERENNIAL ALLERGIC CONJUNCTIVITIS; REVIEW; RHINITIS; URTICARIA;

ANIMALS; ANTIBODIES, ANTI-IDIOTYPIC; ANTIBODIES, MONOCLONAL, HUMANIZED; ASTHMA; CELL DEGRANULATION; HUMANS; HYPERSENSITIVITY; IMMUNOGLOBULIN E; IMMUNOSUPPRESSION; LYMPHOCYTE ACTIVATION; RECEPTORS, IGE; UNITED STATES; UNITED STATES FOOD AND DRUG ADMINISTRATION;

EID: 84866601459     PISSN: 03010546     EISSN: 15781267     Source Type: Journal    
DOI: 10.1016/j.aller.2011.09.011     Document Type: Review

References (99)

1. Holgate S., Casale T., Wenzel S., Bousquet J., Deniz Y., Reisner C. The anti-inflammatory effects of omalizumab confirm the central role of IgE in allergic inflammation. J Allergy Clin Immunol 2005, 115:459-465.
2. MacGlashan D.W., Bochner B.S., Adelman D.C., Jardieu P.M., Togias A., McKenzie-White J., et al. Down-regulation of Fc(epsilon)RI expression on human basophils during in vivo treatment of atopic patients with anti-IgE antibody. J Immunol 1997, 158:1438-1445.
3. Djukanović R., Wilson S.J., Kraft M., Jarjour N.N., Steel M., Chung K.F., et al. Effects of treatment with anti-immunoglobulin E antibody omalizumab on airway inflammation in allergic asthma. Am J Respir Crit Care Med 2004, 170:583-593.
4. Noga O., Hanf G., Brachmann I., Klucken A.C., Kleine-Tebbe J., Rosseau S., et al. Effect of omalizumab treatment on peripheral eosinophil and T-lymphocyte function in patients with allergic asthma. J Allergy Clin Immunol 2006, 117:1493-1499.
5. Prieto L., Gutiérrez V., Colás C., Tabar A., Pérez-Francés C., Bruno L., et al. Effect of omalizumab on adenosine 5'-monophosphate responsiveness in subjects with allergic asthma. Int Arch Allergy Immunol 2006, 139:122-131.
6. Humbert M., Beasley R., Ayres J., Slavin R., Hébert J., Bousquet J., et al. Benefits of omalizumab as add-on therapy in patients with severe persistent asthma who are inadequately controlled despite best available therapy (GINA 2002 step 4 treatment): INNOVATE. Allergy 2005, 60:309-316.
7. van Rensen E.L., Evertse C.E., van Schadewijk W.A., van Wijngaarden S., Ayre G., Mauad T., et al. Eosinophils in bronchial mucosa of asthmatics after allergen challenge: effect of anti-IgE treatment. Allergy 2009, 64:72-80.
8. Solèr M., Matz J., Townley R., Buhl R., O'Brien J., Fox H., et al. The anti-IgE antibody omalizumab reduces exacerbations and steroid requirement in allergic asthmatics. Eur Respir J 2001, 18:254-261.
9. Chipps B., Buhl R., Beeh K.M., Fox H., Thomas K., Reisner C. Improvement in quality of life with omalizumab in patients with severe allergic asthma. Curr Med Res Opin 2006, 22:2201-2208.
10. Limb S.L., Starke P.R., Lee C.E., Chowdhury B.A. Delayed onset and protracted progression of anaphylaxis after omalizumab administration in patients with asthma. J Allergy Clin Immunol 2007, 120:1378-1381.
11. Cox L., Platts-Mills T.A., Finegold I., Schwartz L.B., Simons F.E., Wallace D.V., et al. American Academy of Allergy, Asthma & Immunology/American College of Allergy, Asthma and Immunology Joint Task Force Report on omalizumab-associated anaphylaxis. J Allergy Clin Immunol 2007, 120:1373-1377.
12. Restrepo M., Cardona R., Cardona A. Experience with the use of omalizumab in a patient under 6 years. Int J Immunorehabil 2011, 13:33.
13. Sheikh J. Effect of omalizumab on patients with chronic urticaria: issues with the determination of autoimmune urticaria. Ann Allergy Asthma Immunol 2008, 100:88. author reply -9.
14. Spector S.L., Tan R.A. Effect of omalizumab on patients with chronic urticaria. Ann Allergy Asthma Immunol 2007, 99:190-193.
15. Iemoli E., Piconi S., Fusi A., Borgonovo L., Borelli M., Trabattoni D. Immunological effects of omalizumab in chronic urticaria: a case report. J Investig Allergol Clin Immunol 2010, 20:252-254.
16. Kaplan A.P., Joseph K., Maykut R.J., Geba G.P., Zeldin R.K. Treatment of chronic autoimmune urticaria with omalizumab. J Allergy Clin Immunol 2008, 122:569-573.
17. Kaplan A., Joseph K., Murphy J., Ramey R., Maykut R.K., Zeldin Two year follow-up of patients with chronic autoimmune urticaria treated with omalizumab. J Allergy Clin Immunol 2010, 125:AB67.
18. Vestergaard C., Deleuran M. Two cases of severe refractory chronic idiopathic urticaria treated with omalizumab. Acta Derm Venereol 2010, 90:443-444.
19. Magerl M., Staubach P., Altrichter S., Ardelean E., Krause K., Metz M., et al. Effective treatment of therapy-resistant chronic spontaneous urticaria with omalizumab. J Allergy Clin Immunol 2010, 126:665-666.
20. Metz M., Altrichter S., Ardelean E., Kessler B., Krause K., Magerl M., et al. Anti-immunoglobulin E treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011, 154:177-180.
21. Murphy G.M., Greaves M.W., Zollman P.E., Winkelmann R.K. Cholinergic urticaria, passive transfer experiments from human to monkey. Dermatologica 1988, 177:338-340.
22. Metz M., Altrichter S., Ardelean E., Keβler B., Krause K., Magerl M., et al. Anti-immunoglobulin e treatment of patients with recalcitrant physical urticaria. Int Arch Allergy Immunol 2011, 154:177-180.
23. Waibel K.H., Reese D.A., Hamilton R.G., Devillez R.L. Partial improvement of solar urticaria after omalizumab. J Allergy Clin Immunol 2010, 125:490-491.
24. Güzelbey O., Ardelean E., Magerl M., Zuberbier T., Maurer M., Metz M. Successful treatment of solar urticaria with anti-immunoglobulin E therapy. Allergy 2008, 63:1563-1565.
25. Bullerkotte U., Wieczorek D., Kapp A., Wedi B. Effective treatment of refractory severe heat urticaria with omalizumab. Allergy 2010, 65:931-932.
26. Boyce J.A. Successful treatment of cold-induced urticaria/anaphylaxis with anti-IgE. J Allergy Clin Immunol 2006, 117:1415-1418.
27. Bindslev-Jensen C., Skov P.S. Efficacy of omalizumab in delayed pressure urticaria: a case report. Allergy 2010, 65:138-139.
28. Zuberbier T., Asero R., Bindslev-Jensen C., Walter Canonica G., Church M., Giménez-Arnau A., et al. EAACI/GA(2)LEN/EDF/WAO guideline: definition, classification and diagnosis of urticaria. Allergy 2009, 64:1417-1426.
29. Sabroe R.A. Failure of omalizumab in cholinergic urticaria. Clin Exp Dermatol 2010, 35:e127-e129.
30. Metz M., Bergmann P., Zuberbier T., Maurer M. Successful treatment of cholinergic urticaria with anti-immunoglobulin E therapy. Allergy 2008, 63:247-249.
31. Callejas-Rubio J.L., Sánchez-Cano D., Lara M.A., Ortego-Centeno N. Omalizumab as a therapeutic alternative for chronic urticaria. Ann Allergy Asthma Immunol 2008, 101:556.
32. Sands M.F., Blume J.W., Schwartz S.A. Successful treatment of 3 patients with recurrent idiopathic angioedema with omalizumab. J Allergy Clin Immunol 2007, 120:979-981.
33. Caruso C., Gaeta F., Valluzzi R.L., Romano A. Omalizumab efficacy in a girl with atopic eczema. Allergy 2010, 65:278-279.
34. Park S.Y., Choi M.R., Na J.I., Youn S.W., Park K.C., Huh C.H. Recalcitrant atopic dermatitis treated with omalizumab. Ann Dermatol 2010, 22:349-352.
35. Lane J.E., Cheyney J.M., Lane T.N., Kent D.E., Cohen D.J. Treatment of recalcitrant atopic dermatitis with omalizumab. J Am Acad Dermatol 2006, 54:68-72.
36. Belloni B., Ziai M., Lim A., Lemercier B., Sbornik M., Weidinger S., et al. Low-dose anti-IgE therapy in patients with atopic eczema with high serum IgE levels. J Allergy Clin Immunol 2007, 120:1223-1225.
37. Sheinkopf L.E., Rafi A.W., Do L.T., Katz R.M., Klaustermeyer W.B. Efficacy of omalizumab in the treatment of atopic dermatitis: a pilot study. Allergy Asthma Proc 2008, 29:530-537.
38. Heil P.M., Maurer D., Klein B., Hultsch T., Stingl G. Omalizumab therapy in atopic dermatitis: depletion of IgE does not improve the clinical course-a randomized, placebo-controlled and double blind pilot study. J Dtsch Dermatol Ges 2010, 8:990-998.
39. Bonadonna P., Zanotti R., Müller U. Mastocytosis and insect venom allergy. Curr Opin Allergy Clin Immunol 2010, 10:347-353.
40. Golden D.B. Long-term outcome after venom immunotherapy. Curr Opin Allergy Clin Immunol 2010, 10:337-341.
41. Demain J.G., Minaei A.A., Tracy J.M. Anaphylaxis and insect allergy. Curr Opin Allergy Clin Immunol 2010, 10:318-322.
42. Haeberli G., Brönnimann M., Hunziker T., Müller U. Elevated basal serum tryptase and hymenoptera venom allergy: relation to severity of sting reactions and to safety and efficacy of venom immunotherapy. Clin Exp Allergy 2003, 33:1216-1220.
43. Ramírez R.H., Cardona R., Serrano C. Alergia a la picadura de himenópteros 2010, Alergia: abordaje clínico, diagnostico y tratamiento, Bogotá.
44. Finegold I. Issues in stinging insect allergy immunotherapy: a review. Curr Opin Allergy Clin Immunol 2008, 8:343-347.
45. Galera C., Soohun N., Zankar N., Caimmi S., Gallen C., Demoly P. Severe anaphylaxis to bee venom immunotherapy: efficacy of pretreatment and concurrent treatment with omalizumab. J Investig Allergol Clin Immunol 2009, 19:225-229.
46. Schulze J., Rose M., Zielen S. Beekeepers anaphylaxis: successful immunotherapy covered by omalizumab. Allergy 2007, 62:963-964.
47. Rerinck H.C.R.F., Przybilla B. Recurrent severe anaphylactic reactions to venom immunotherapy (VIT): omalizumab induces tolerance. J Allergy Clin Immunol 2008, 121:s29-s111.
48. Kontou-Fili K., Filis C.I. Prolonged high-dose omalizumab is required to control reactions to venom immunotherapy in mastocytosis. Allergy 2009, 64:1384-1385.
49. Zuberbier T., Asero R., Bindslev-Jensen C., Walter Canonica G., Church M.K., Giménez-Arnau A.M., et al. EAACI/GA(2)LEN/EDF/WAO guideline: management of urticaria. Allergy 2009, 64:1427-1443.
50. Jones J.D., Marney S.R., Fahrenholz J.M. Idiopathic anaphylaxis successfully treated with omalizumab. Ann Allergy Asthma Immunol 2008, 101:550-551.
51. Warrier P., Casale T.B. Omalizumab in idiopathic anaphylaxis. Ann Allergy Asthma Immunol 2009, 102:257-258.
52. Simons F.E. 9. Anaphylaxis. J Allergy Clin Immunol 2008, 121(Suppl. 2):S402-S407. quiz S20.
53. Akin C., Valent P., Metcalfe D.D. Mast cell activation syndrome: proposed diagnostic criteria. J Allergy Clin Immunol 2010, 126. 1099-1104.e4.
54. Carter M.C., Robyn J.A., Bressler P.B., Walker J.C., Shapiro G.G., Metcalfe D.D. Omalizumab for the treatment of unprovoked anaphylaxis in patients with systemic mastocytosis. J Allergy Clin Immunol 2007, 119:1550-1551.
55. Douglass J.A., Carroll K., Voskamp A., Bourke P., Wei A., O'Hehir R.E. Omalizumab is effective in treating systemic mastocytosis in a nonatopic patient. Allergy 2010, 65:926-927.
56. Pitt T.J., Cisneros N., Kalicinsky C., Becker A.B. Successful treatment of idiopathic anaphylaxis in an adolescent. J Allergy Clin Immunol 2010, 126:415-416. author reply 6.
57. Bonini S., Gramiccioni C., Bonini M., Bresciani M. Practical approach to diagnosis and treatment of ocular allergy: a 1-year systematic review. Curr Opin Allergy Clin Immunol 2007, 7:446-449.
58. Okubo K., Ogino S., Nagakura T., Ishikawa T. Omalizumab is effective and safe in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Allergol Int 2006, 55:379-386.
59. Ogino S., Nagakura T., Okubo K., Sato N., Takahashi M., Ishikawa T. Re-treatment with omalizumab at one year interval for Japanese cedar pollen-induced seasonal allergic rhinitis is effective and well tolerated. Int Arch Allergy Immunol 2009, 149:239-245.
60. Nagakura T., Ogino S., Okubo K., Sato N., Takahashi M., Ishikawa T. Omalizumab is more effective than suplatast tosilate in the treatment of Japanese cedar pollen-induced seasonal allergic rhinitis. Clin Exp Allergy 2008, 38:329-337.
61. Casale T.B., Condemi J., LaForce C., Nayak A., Rowe M., Watrous M., et al. Effect of omalizumab on symptoms of seasonal allergic rhinitis: a randomized controlled trial. JAMA 2001, 286:2956-2967.
62. Brownell J., Casale T.B. Anti-IgE therapy. Immunol Allergy Clin North Am 2004, 24:551-568. v.
63. Williams P.B., Sheppard J.D. Omalizumab: a future innovation for treatment of severe ocular allergy?. Expert Opin Biol Ther 2005, 5:1603-1609.
64. Sanchez J., Diez S., Restrepo M., Chinchilla C., Cardona R. Omalizumab ¿Una opción en la Queratoconjuntivitis vernal??. Revista Brasilera de Alergia e Imunopatologia 2010, 33:130.
65. Gonsalves N. Food allergies and eosinophilic gastrointestinal illness. Gastroenterol Clin North Am 2007, 36:75-91. vi.
66. Rothenberg M.E. Eosinophilic gastrointestinal disorders (EGID). J Allergy Clin Immunol 2004, 113:11-28. quiz 9.
67. Blanchard C., Wang N., Rothenberg M.E. Eosinophilic esophagitis: pathogenesis, genetics, and therapy. J Allergy Clin Immunol 2006, 118:1054-1059.
68. Blanchard C., Wang N., Stringer K.F., Mishra A., Fulkerson P.C., Abonia J.P., et al. Eotaxin-3 and a uniquely conserved gene-expression profile in eosinophilic esophagitis. J Clin Invest 2006, 116:536-547.
69. Khan S., Orenstein S.R. Eosinophilic gastroenteritis. Gastroenterol Clin North Am 2008, 37:333-348. v.
70. Stone K.D., Prussin C. Immunomodulatory therapy of eosinophil-associated gastrointestinal diseases. Clin Exp Allergy 2008, 38:1858-1865.
71. Foroughi S., Foster B., Kim N., Bernardino L.B., Scott L.M., Hamilton R.G., et al. Anti-IgE treatment of eosinophil-associated gastrointestinal disorders. J Allergy Clin Immunol 2007, 120:594-601.
72. Riffelmann F. Anti IgE therapy (off label use) in severe peanut allergy with recurrent anaphylaxis. Pneumologie 2008, 62:337-339.
73. Plaza-Martin A.M., Giner-Muñoz M.T., Dominguez-Sanchez O., Piquer-Gibert M., Martin-Mateos M.A. Omalizumab and the induction of tolerance to cow's milk proteins in children at high risk of anaphylaxis. J Allergy Clin Immunol 2009, 123:s26.
74. Menzella F., Facciolongo N., Castagnetti C., Simonazzi A., Zucchi L. Omalizumab: when the non-responder is a late-responder. Eur Ann Allergy Clin Immunol 2009, 41:155-159.
75. Rafi A., Do L.T., Katz R., Sheinkopf L.E., Simons C.W., Klaustermeyer W. Effects of omalizumab in patients with food allergy. Allergy Asthma Proc 2010, 31:76-83.
76. Leung D.Y., Sampson H.A., Yunginger J.W., Burks A.W., Schneider L.C., Wortel C.H., et al. Effect of anti-IgE therapy in patients with peanut allergy. N Engl J Med 2003, 348:986-993.
77. Sampson H.A. Utility of food-specific IgE concentrations in predicting symptomatic food allergy. J Allergy Clin Immunol 2001, 107:891-896.
78. Pollart S.M., Warniment C., Mori T. Latex allergy. Am Fam Physician 2009, 80:1413-1418.
79. Rolland J.M., O'Hehir R.E. Latex allergy: a model for therapy. Clin Exp Allergy 2008, 38:898-912.
80. Sastre J., Quirce S. Immunotherapy: an option in the management of occupational asthma?. Curr Opin Allergy Clin Immunol 2006, 6:96-100.
81. Leynadier F., Doudou O., Gaouar H., Le Gros V., Bourdeix I., Guyomarch-Cocco L., et al. Effect of omalizumab in health care workers with occupational latex allergy. J Allergy Clin Immunol 2004, 113:360-361.
82. Siebenhaar F., Kühn W., Zuberbier T., Maurer M. Successful treatment of cutaneous mastocytosis and Ménière disease with anti-IgE therapy. J Allergy Clin Immunol 2007, 120:213-215.
83. Ruckenstein M.J. Immunologic aspects of Meniere's disease. Am J Otolaryngol 1999, 20:161-165.
84. Winchester D.E., Jacob A., Murphy T. Omalizumab for asthma. N Engl J Med 2006, 355:1281-1282.
85. Marzano A.V., Ramoni S., Spinelli D., Alessi E., Berti E. Refractory linear IgA bullous dermatosis successfully treated with mycophenolate sodium. J Dermatol Treat 2008, 19:364-367.
86. Ruppert A.M., Averous G., Stanciu D., Deroide N., Riehm S., Poindron V., et al. Development of Churg-Strauss syndrome with controlled asthma during omalizumab treatment. J Allergy Clin Immunol 2008, 121:253-254.
87. Giavina-Bianchi P., Giavina-Bianchi M., Agondi R., Kalil J. Administration of anti-IgE to a Churg-Strauss syndrome patient. Int Arch Allergy Immunol 2007, 144:155-158.
88. Giavina-Bianchi P., Giavina-Bianchi M., Agondi R., Kalil J. Omalizumab and Churg-Strauss syndrome. J Allergy Clin Immunol 2008, 122:217. author reply -8.
89. Pabst S., Tiyerili V., Grohé C. Apparent response to anti-IgE therapy in two patients with refractory "forme fruste" of Churg-Strauss syndrome. Thorax 2008, 63:747-748.
90. Chularojanamontri L., Wimoolchart S., Tuchinda P., Kulthanan K., Kiewjoy N. Role of omalizumab in a patient with hyper-IgE syndrome and review dermatologic manifestations. Asian Pac J Allergy Immunol 2009, 27:233-236.
91. Bard S., Paravisini A., Avilés-Izquierdo J.A., Fernandez-Cruz E., Sánchez-Ramón S. Eczematous dermatitis in the setting of hyper-IgE syndrome successfully treated with omalizumab. Arch Dermatol 2008, 144:1662-1663.
92. Greenberger P.A. Allergic bronchopulmonary aspergillosis. J Allergy Clin Immunol 2002, 110:685-692.
93. Brinkmann F., Schwerk N., Hansen G., Ballmann M. Steroid dependency despite omalizumab treatment of ABPA in cystic fibrosis. Allergy 2010, 65:134-135.
94. Randhawa I., Chin T., Nussbaum E. Resolution of corticosteroid-induced diabetes in allergic bronchopulmonary aspergillosis with omalizumab therapy: a novel approach. J Asthma 2009, 46:445-447.
95. Lebecque P., Leonard A., Pilette C. Omalizumab for treatment of ABPA exacerbations in CF patients. Pediatr Pulmonol 2009, 44:516.
96. Kanu A., Patel K. Treatment of allergic bronchopulmonary aspergillosis (ABPA) in CF with anti-IgE antibody (omalizumab). Pediatr Pulmonol 2008, 43:1249-1251.
97. Zirbes J.M., Milla C.E. Steroid-sparing effect of omalizumab for allergic bronchopulmonary aspergillosis and cystic fibrosis. Pediatr Pulmonol 2008, 43:607-610.
98. van der Ent C.K., Hoekstra H., Rijkers G.T. Successful treatment of allergic bronchopulmonary aspergillosis with recombinant anti-IgE antibody. Thorax 2007, 62:276-277.
99. Quintás Vázquez L.M., Ortiz Piquer M., Pérez de Llano L.A. Effective anti-immunoglobulin-E antibody treatment of a patient with allergic bronchopulmonary aspergillosis. Arch Bronconeumol 2009, 45:207.